FIG 5.

In vivo antileishmanial effect of compound 4c. In vivo leishmanicidal efficacy of compound 4c in BALB/c mice infected with AG83 promastigotes via intracardiac route was determined. Compound 4c was given at a dosage of 1, 2.5, 5, and 10 mg/kg of body weight intraperitoneally for 3 weeks (2 times per week) starting on day 21 after infection. Animals were sacrificed 10 days after treatment, and liver (A) and splenic (B) parasite loads were determined for all groups. Untreated infected mice were used as controls. Liver and spleen parasite burdens were determined by the stamp-smear method and expressed as LDU. Data represent mean ± SEM (n = 5 mice per group). *, P < 0.01; **, P < 0.001 (by Student's t test for different compound 4c treatment groups compared to the infection control).